Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | F13A1 | P00488 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | TGM1 | P22735 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30418583 | 0.86 | USP2 (0.43) | SMN1; SMN2USP2CHRM2CHRM4CHRM1 | |
| SCHEMBL17532546 | 0.83 | USP2 (0.45) | SMN1; SMN2USP2CHRM2CHRM4CHRM1 | |
| SCHEMBL14165640 | 0.83 | USP2 (0.45) | SMN1; SMN2USP2CHRM2CHRM4CHRM1 | |
| SCHEMBL14165639 | 0.83 | USP2 (0.45) | SMN1; SMN2USP2CHRM2CHRM4CHRM1 | |
| SCHEMBL16113676 | 0.81 | HCAR2 (0.44) | SMN1; SMN2ALDH1A1POLBHTTMAPT | |
| SCHEMBL16114006 | 0.81 | HCAR2 (0.44) | SMN1; SMN2ALDH1A1POLBHTTMAPT | |
| SCHEMBL26430057 | 0.80 | USP2 (0.47) | SMN1; SMN2USP2CHRM2CHRM4CHRM1 | |
| SCHEMBL7282919 | 0.79 | KDM4E (0.43) | SMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL7285037 | 0.79 | KDM4E (0.43) | SMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL1189317 | 0.79 | ALDH1A1 (0.56) | SMN1; SMN2USP2ALDH1A1POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723753-B2 | Ras inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| WO-2014160200-A9 | RAS INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-11-27 | — | — | WO | disclosed |
| WO-2014160200-A1 | RAS INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723753-B2 | Ras inhibitors and uses thereof | KRAS, NRAS, RASGRP1 | SMN1; SMN2 4846/4885USP2 1402/4885CHRM2 4686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.